Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Hull
R D
RD
Liang
J
J
Brant
R
R
D000284:Administration, Oral; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000401:mortality; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000401:mortality; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D000069604:Dabigatran; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D017558:Elective Surgical Procedures; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007279:Injections, Subcutaneous; D015201:Meta-Analysis as Topic; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000209:etiology / Q000401:mortality / Q000517:prevention & control
D001562:Benzimidazoles; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D011725:Pyridines; D000069604:Dabigatran